Navigation Links
China-Biotics, Inc. Reports First Quarter 2009 Financial Results

SHANGHAI, China, Aug. 14 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics, Inc. (OTC Bulletin Board: CHBT) (''China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced its financial results for the first quarter of its 2009 fiscal year, ended June 30, 2008.

First Quarter 2009 Highlights

-- Net sales increased 19.5% year-over-year to $11.4 million

-- Gross profit increased 18.2% year-over-year to $8.1 million

-- Gross margin was 71.3%, up from 66.3% in the fourth quarter of 2008

-- Net income was $3.2 million

-- Excluding a $1.2 million loss related to the change in fair value of

convertible notes, net income increased 26.4% year-over-year to $4.5

million, or $0.23 per diluted share

-- Added 23 retail outlets during the quarter, bringing the total number

of outlets to 83 in nine cities in China

-- Signed agreement with a subsidiary of Holiland Enterprise Investment

Management Co., Ltd. (''Holiland'') to supply probiotics for Holiland's

bakery products

-- Signed agreement with Jiangxi Lijia Pharmaceutical Co., Ltd. ("Lijia")

to supply probiotics for Lijia's probiotics-based dietary supplements

in both powder and tablet forms

-- Established three board committees in preparation for future stock

exchange listing

-- Filed application for listing approval on the Nasdaq Global Market

First Quarter 2009 Results

During the first quarter of the 2009 fiscal year, net sales increased 19.5% to $11.4 million from $9.5 million the prior year. The increase primarily resulted from growth in the sales volume of new products and increases in the sales price of selected products. These new products, including Shining Essence Stomach Protection Capsules and Shining Probiotics Protein Powder, accounted for 1 434,924 590,026

Increase/(Decrease) in

income tax, surcharge tax

and dividends withholding tax 588,686 622,305

Increase/(Decrease) in

other payables and

accruals, and value added

tax payable (136,326) 130,688

Increase/(Decrease) in

interest payables (121,402) --


OPERATING ACTIVITIES $ 8,347,674 $ 7,761,471



Purchases of fixed assets (7,193,855) (533,080)



Effect of exchange rate

changes on cash $ 740,436 $ 474,448


CASH EQUIVALENTS BALANCES $ 1,894,255 $ 7,702,839



PERIOD 64,310,448 26,992,025


BALANCES AT END OF PERIOD $ 66,204,703 $ 34,694,864



Three Months ended Three Months ended

Non-GAAP Net income June 30, 2008 June 30, 2007

Net Income (Loss) Net Income Net Income

Adjusted Amount 4,475,750 $ 3,540,233


Non-cash loss from change

in fair value of

convertible bonds $ 1,239,000 --

Amount per consolidated statement

of operations $ 3,236,750 $ 3,540,233

For more information, please contact:

CCG Investor Relations

Crocker Coulson, President

Phone: +1-646-213-1915 (New York)



6.6% of total sales during the quarter, up from 5.0% a year ago. Sales of bulk additives to commercial customers totaled $1.0 million, or 8.8% of sales, during the first quarter of 2009, contributing meaningful sales for the first time.

''We are pleased with this strong beginning to the 2009 fiscal year, and we are confident in our retail expansion and bulk additive business development strategies,'' said Mr. Jinan Song, Chairman and Chief Executive Officer of China-Biotics. "We have accelerated the pace of new customer acquisition for our additive business in preparation for launching our new plant. Currently, we are in negotiations with another 50 potential business clients. Of these, 30 have begun or completed sample testing for their probiotics-based products. We look forward to increasing the number of business customers in order to occupy the capacity of our new plant when it is up and running.''

Gross profit during the first quarter increased 18.2% to $8.1 million from $6.9 million in the first quarter of 2008. Gross margin was 71.3%, down slightly from 72.1% a year ago. Gross margin improved sequentially 5 percentage points from 66.3% in the fourth quarter of 2008, as the Company was able to increase prices on selected products.

Operating expenses increased to $3.8 million from $2.1 million in the first quarter of fiscal 2008. The increase was attributed to setup and operations costs for new retail outlets; increased salary expense stemming from new hires to support the Company's expansion; and additional research costs associated with the development and launch of new products. As of June 30, 2008, the Company had 339 employees and operated 83 Shining-branded retail outlets, up from 208 employees and 14 Shining outlets on June 30, 2007.

Operating income for the quarter was $4.3 million, compared to $4.7 million a year ago.

Other expense of $1.2 million in the first quarter of 2009 consisted of a $1.2 million book loss recorded in the first quarter of 2009 related to the change in the fair value of the $25 million convertible notes issued in December 2007.

Net income for the first quarter of the 2009 fiscal year was $3.2 million. Excluding the $1.2 million loss on the revaluation of the convertible notes, net income was $4.5 million, up from $3.5 million in the same quarter of the prior year.

Diluted earnings per share were $0.23 calculated on a weighted average basis, compared with $0.21 per diluted share in the first quarter of fiscal 2008. The calculation of diluted earnings per share for the first quarter of 2008 assumes full conversion of the convertible notes and thus excludes the loss from the change in fair value of the notes.

Financial Condition

As of June 30, 2008, the Company had cash and cash equivalents of $66.2 million and working capital of $50.7 million. The increase in cash resulted in part from the private placement of $25 million of the Company's convertible notes in December 2007. In the first quarter of 2009, China-Biotics generated $8.3 million in cash flow from operations and recorded $7.2 million in capital expenditures related to the construction of the new manufacturing facility. Accounts receivable declined to $10.7 million from $13.2 million on March 31, 2008, and days' sales outstanding for the first quarter of 2009 was 96 days. At June 30, 2008, the Company had stockholders' equity of $48.5 million.

Business Outlook

The Company's new bulk additives production facility remains scheduled to begin production in the Company's fiscal third quarter. As of June 30, 2008, China-Biotics had signed contracts with four business customers to supply those customers with bulk probiotics in powder form that can be added to products such as milk, ice cream, yogurt, baked goods and nutritional supplements.

The Company's retail strategy is also on schedule, with 83 Shining retail outlets open as of June 30, 2008, in Shanghai and eight other cities in China. Management continues to work toward its goal of operating 300 Shining outlets by the end of the Company's 2009 fiscal year.

''As our retail and bulk additives businesses continue to expand, we are managing our capacity utilization carefully to strike a balance between achieving current and future sales growth,'' Mr. Song said. ''We are pleased that we were able to begin achieving meaningful sales of our bulk additives to commercial customers. We are also working on rolling out new retail outlets as quickly as we can. Those outlets already open more than one year have demonstrated tremendous year-over-year sales growth, and we believe that, in time, the retail strategy will contribute significantly to our growth. Meanwhile, construction of our new bulk additives facility is on schedule, and we continue working to add new customers in that segment in preparation for the plant coming online at the end of this calendar year.''

Recent Events

On July 9, 2008, Dr. Shuguang Fang, China-Biotics' Chief Technology Officer, was the guest speaker at China's 3rd Annual Food Safety Technology Forum 2008. Dr. Fang spoke on the importance of probiotics safety in dairy products.

Also in July 2008, China-Biotics announced the appointment of American Stock Transfer & Trust Company as its new transfer agent and registrar, effective August 15, 2008. AST, headquartered in New York City, replaces the Company's former transfer agent and registrar, American Registrar & Transfer Company.

On July 18, 2008, the Company announced it has applied for listing approval on the Nasdaq Global Market. The application is subject to review by Nasdaq's Listing Qualifications Department for compliance with all Nasdaq Global Market requirements. The Company's common stock will continue to trade on the OTC Bulletin Board under its current symbol, CHBT, until the Company is notified of its acceptance, which it hopes to receive within two to three months.

Conference Call

The company will host a conference call at 9:00 a.m. EDT on, Friday, August 15, 2008, to discuss its financial results for the fiscal first quarter ended June 30, 2008. To participate in the event by telephone, please dial (888) 241-0558 five to 10 minutes prior to the start time (to allow time for registration) and reference passcode 58187212. International callers should dial 647-427-3417. The conference call will be broadcast live over the Internet and can be accessed by all interested parties at the Company's Web site, . To listen to the call, please visit the site at least 15 minutes prior to the start of the call to register, download, and install any necessary audio software. For those unable to participate during the live webcast, it will be archived using the same link for 90 days. A digital replay of the call will also be available on Friday, August 15, at approximately 11:00 a.m. EDT through Friday, August 22, at midnight EDT. Dial (800) 678-0453 and enter the conference ID number 58187212. International callers should dial (402) 220-1458 and enter the same conference ID number.

Use of Non-GAAP Financial Information

GAAP results for the first quarter ended June 30, 2008, include a non-cash loss related to the change in fair value of the Company's convertible notes. To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of this item, which is non-GAAP net income, in this release. The Company's management believes that this non-GAAP measure provides investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of adjustments to GAAP results appears in the table accompanying this press release. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.

About China-Biotics, Inc.

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the ''Shining'' brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, ability to access to capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.




(Amounts expressed in US Dollars)

Three months ended June 30,

2008 2007

Net sales $ 11,370,657 $ 9,515,333

Cost of sales (3,258,669) (2,650,972)

Gross profit $ 8,111,988 $ 6,864,361

Operating expenses:

Selling expenses $ (2,369,859) $ (1,316,344)

General and administrative expenses (1,426,797) (809,564)

Total operating expenses $ (3,796,656) $ (2,125,908)

Income from operations $ 4,315,332 $ 4,738,453

Other income and expenses:

Changes in the fair value of

embedded derivatives (1,239,000) --

Other income $ 1,538,889 $ 71,660

Other expenses -- (6,924)

Total other income (expenses) $299,889 $ 64,736

Income before taxes $ 4,615,221 $ 4,803,189

Provision for income taxes (1,378,471) (1,262,956)

Net income $ 3,236,750 $ 3,540,233

Earnings per share:

Basic $ 0.19 $ 0.21

Diluted $ 0.23 $ 0.21

Weighted average shares outstanding

Basic 17,080,000 17,080,000

Diluted 19,163,333 17,080,000



(Amounts expressed in US Dollars)

As of June 30, As of March 31,

2008 2008


Current assets

Cash and cash equivalents $ 66,204,703 $ 64,310,448

Accounts receivable 10,669,699 13,214,531

Other receivables 241,083 238,835

Inventories 617,260 408,358

Prepayment 1,634,253 1,806,605

Total current assets $ 79,366,998 $ 79,978,777

Property, plant and equipment and

land use right 22,186,275 13,812,749

Total assets $ 101,553,273 $ 93,791,526


Current liabilities:

Accounts payable $ 3,287,603 $ 2,786,180

Tax payables 23,321,183 22,317,982

Other payables and accruals 2,012,365 1,792,156

Total current liabilities $ 28,621,151 $ 26,896,318

Non-current liabilities

Convertible note, with embedded

derivatives of $6,991,000, net of

discount of $7,963,557 as of June

30, 2008 $ 24,027,443 $ 22,197,635

Interest payable 446,763 302,306

Total non-current liabilities $ 24,474,206 $ 22,499,941

Commitments and contingencies

Stockholders' equity:

Common stock (par value of $0.0001,

100,000,000 shares authorized,

41,461,004 shares issued and

outstanding as of June 30, 2008) $ 4,146 $ 4,146

Additional paid-in capital 7,863,031 7,863,031

Retained earnings 33,063,894 29,827,144

Treasury stock at cost (24,381,004

shares) (2,438) (2,438)

Accumulated other comprehensive

income 4,503,489 3,677,590

Capital and statutory reserves 3,025,794 3,025,794

Total stockholders' equity $ 48,457,916 $ 44,395,267

Total liabilities and stockholders'

equity $ 101,553,273 $ 93,791,526



(Amounts expressed in US Dollars)

Three months ended

June 30,

2008 2007


Net income $ 3,236,750 $ 3,540,233

Adjustment for:

Changes in the fair value

of embedded derivatives 1,239,000 --

Depreciation 298,691 142,310

(Increase)/Decrease in

accounts receivable 2,793,079 2,786,747

(Increase)/Decrease in inventories (197,308) 6,318

(Increase)/Decrease in prepayments 211,580 (57,156)

Increase/(Decrease) in

accounts payable

SOURCE China-Biotics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. China-Biotics, Inc. Files Application for Nasdaq Listing
3. China-Biotics, Inc. Announces Appointment of New Transfer Agent Effective August 15, 2008
4. China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results
5. China-Biotics, Inc. to Present at Chinas 3rd Annual Food Safety Technology Forum 2008
6. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2008 Results
7. China-Biotics, Inc. to Supply Probiotics to Pharmaceutical Company
8. China-Biotics, Inc. to Present at Two Upcoming Investor Conferences
9. China-Biotics, Inc. Completes Foundation for Its New Plant
10. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
11. China-Biotics, Inc. Announces Rescheduling of Conference Call to Discuss Third Quarter 2008 Results
Post Your Comments:
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... recipients of 13 prestigious awards honoring scientists who have made ... in a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board ... Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has been selected ... member of the winning team for the 2015 Breakthrough Prize in Fundamental physics for ...
(Date:10/7/2017)... (PRWEB) , ... October 06, ... ... years’ experience providing advanced instruments and applications consulting for microscopy and surface ... expertise in application consulting, Nanoscience Analytical offers a broad range of contract ...
(Date:10/6/2017)... ... 2017 , ... The HealthTech Venture Network (HTVN) is proud ... annual Conference where founders, investors, innovative practitioners and collaborators are invited to a ... early stage digital health and med tech companies. , This day-long event will ...
Breaking Biology Technology:
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):